Application of Tibetan tea in preparation of medicine for improving, preventing or treating intestinal dysfunction

Through the extract of Aoya An An Tibetan Tea for ten years, the problem of intestinal dysfunction caused by sleep deprivation is solved. By reducing ROS accumulation and inflammatory factors in the intestinal tract, it significantly improves intestinal inflammation and barrier dysfunction, providing intestinal diseases with the provision of intestinal diseases. New treatment options are available and are safe and non-toxic.

CN118924826APending Publication Date: 2024-11-12WEST CHINA HOSPITAL SICHUAN UNIV +1
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202410987971.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-23
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

There is currently a lack of effective preventive or therapeutic measures to deal with intestinal diseases induced by sleep deprivation, especially intestinal dysfunction.

Method used

The preferred ten-year-old Aged Ya'an Tibetan Tea was used for extraction, and the Tibetan Tea extract was obtained by crushing, water bath extraction and drying, and its effect in reducing ROS accumulation and inflammatory factor levels in the intestinal tract was verified by animal models.

Benefits of technology

Tibetan tea extract significantly reduces the accumulation of reactive oxygen species in the intestines, downregulates inflammatory factors, maintains intestinal barrier function, and provides an effective means to prevent and treat intestinal inflammation and barrier function disorders induced by sleep deprivation, and it comes from food. Tea is safe and non-toxic, mild and has no obvious side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924826A_ABST
    Figure CN118924826A_ABST
Patent Text Reader

Abstract

The invention discloses application of Tibetan tea in preparation of a medicine for improving, preventing or treating intestinal dysfunction. The intestinal dysfunction is induced by sleep deprivation. The research finds that the Tibetan tea extract can obviously relieve the intestinal dysfunction symptom of a sleep deprivation model mouse, the novel application of the Tibetan tea and the novel pharmaceutical composition for treating the intestinal dysfunction are provided for the problem that medicines for treating the intestinal dysfunction are limited, the effect is obvious, the source is safe, the effect is mild, no obvious side effect exists, and the Tibetan tea extract can be used for treating the intestinal dysfunction. Good application prospects are realized.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of extraction and application of natural health food, and in particular to use of Tibetan tea in preparing medicine for improving, preventing or treating intestinal dysfunction. Background Art

[0002] The statements in this section merely provide background information related to the present disclosure and may not constitute prior art.

[0003] In the latest research, the association between intestinal oxidative stress and intestinal inflammatory diseases has become increasingly clear. Oxidative stress refers to the imbalance between the production of free radicals and the antioxidant system in the body. This imbalance can lead to damage to cellular components and trigger an inflammatory response. In intestinal inflammatory diseases such as Crohn's Disease and Ulcerative Colitis, oxidative stress is considered to be one of the important factors in the pathological process. Studies have shown that oxidative stress can activate immune cells in the intestinal mucosa and release inflammatory mediators such as tumor necrosis factor α (TNF-α) and interleukin 6 (IL-6), which can aggravate intestinal mucosal damage and inflammatory response. In addition, oxidative stress can also aggravate inflammation by affecting intestinal barrier function, increasing intestinal permeability, and promoting the penetration of exogenous antigens. The use of antioxidants shows potential in the treatment of intestinal inflammatory diseases. For example, vitamins E and C can reduce oxidative stress and reduce inflammatory responses. In addition, some plant extracts have also been found to have antioxidant and anti-inflammatory effects and may become part of the treatment strategy.

[0004] In recent years, the quality of human life has been greatly improved. However, with the fast pace and high pressure of urban life, more and more people have trouble sleeping. Sleep deprivation (SD) refers to a sleep duration shorter than the average basic requirement of seven to eight hours per night. In a study of SD in animals, it was found that the intestine (including the small intestine and large intestine) is the main target organ for the accumulation of reactive oxygen species (ROS) in the body caused by SD. This accumulation of ROS in the intestine will eventually lead to a serious shortening of the lifespan of experimental animals. Clinical studies on humans have shown that there is a strong association between SD and human gastrointestinal diseases. Based on the correlation between oxidative stress and intestinal diseases, the accumulation of intestinal ROS caused by SD is likely to be the key cause of intestinal inflammatory diseases.

[0005] Tibetan tea is mainly produced in Ya'an, Sichuan. It is a typical black tea and a post-fermented tea. It is the main drink for Tibetan compatriots in Sichuan and Tibet. Tibetan tea, as a thousand-year-old tea, is picked from mountains above 1,000 meters above sea level and refined through a series of processes including withering, rolling, piling and drying. Tibetan tea has antioxidant, anti-inflammatory and anti-infective effects and has been considered a natural and effective health drink. Its intake plays an important role in maintaining the health of the people in Tibetan areas, so much so that there is a saying that "one day without tea will lead to stagnation, and three days without tea will lead to illness". Because the people in Tibetan areas live in high-altitude mountainous areas and plateaus, their food is mainly high-fat and high-protein butter, meat, and dairy products, and they lack the intake of fresh vegetables and fruits rich in reducing vitamins. This environment and dietary structure easily cause oxidative stress burden on the digestive tract. In addition to being rich in soluble dietary fiber, Tibetan tea also contains a variety of antioxidant active substances such as tea polyphenols, flavonoids and theaflavins. Therefore, these natural products in Tibetan tea, in addition to promoting intestinal peristalsis, are likely to play a key role in clearing excess ROS in the intestine and maintaining oxidation-reduction homeostasis to protect intestinal health. Summary of the invention

[0006] The purpose of the present invention is to address the problem that there is currently no clear and specific prevention or treatment recommendation for intestinal diseases induced by sleep deprivation. The present invention provides a use of Tibetan tea in the preparation of a medicament for improving, preventing or treating intestinal dysfunction, thereby solving the problem of targeted treatment of intestinal diseases induced by sleep deprivation.

[0007] The technical solution of the present invention is as follows:

[0008] In one aspect, the present invention provides a use of Tibetan tea in preparing a medicine for improving, preventing or treating intestinal dysfunction.

[0009] The Tibetan tea of ​​the present application is Ya'an Tibetan tea implemented in accordance with the supply and marketing cooperative industry standard GH / T 1120-2015 of the People's Republic of China. Preferably, it is ten-year aged Tibetan tea.

[0010] According to a preferred embodiment, the intestinal dysfunction is induced by sleep deprivation.

[0011] Another aspect of the present invention provides a pharmaceutical composition for improving, preventing or treating intestinal dysfunction, wherein the pharmaceutical composition comprises a Tibetan tea extract.

[0012] According to a preferred embodiment, the Tibetan tea extract is prepared according to the following method:

[0013] Step S1: grind the Tibetan tea with a 40-mesh screen grinder to obtain tea powder;

[0014] Step S2: Mix water and the tea powder of step S1 in a mass ratio of 20:1, isolate from air, extract in a boiling water bath at 90-100° C. for 30 minutes, and filter through a 0.45 μm filter membrane after cooling to obtain a tea supernatant;

[0015] Step S3: Dry the tea supernatant to remove water to obtain the Tibetan tea extract.

[0016] According to a preferred embodiment, in step S2, the drying method is freeze-drying at -80°C to obtain the Tibetan tea extract.

[0017] The Tibetan tea extract is stored for future use. The Tibetan tea extract needs to be stored in a sealed container away from light, preferably in a sealed container away from light at 4-25°C.

[0018] According to a preferred embodiment, the intestinal dysfunction is induced by sleep deprivation.

[0019] According to a preferred embodiment, the intestinal dysfunction is characterized by accumulation of intestinal reactive oxygen species (ROS), increased oxidative stress marker MDA and decreased SOD activity, damaged intestinal goblet cells, and increased inflammatory factors such as TNF-α, IL-1β and IL-6.

[0020] Compared with the prior art, the present invention has the following beneficial effects:

[0021] 1. A use of Tibetan tea in preparing a drug for improving, preventing or treating intestinal dysfunction. The present invention uses sleep deprivation (SD) as a means to construct an intestinal oxidative stress animal model, and finds that the intervention of Tibetan tea extract can effectively reduce the accumulation of ROS in the intestine of the model animal, downregulate the inflammatory factors in the intestine and plasma, and maintain the intestinal barrier function of the model animal, indicating that the Tibetan tea extract has a good application prospect in the preparation of drugs for preventing / treating / alleviating intestinal inflammation and barrier dysfunction induced by sleep deprivation;

[0022] 2. A use of Tibetan tea in the preparation of a medicine for improving, preventing or treating intestinal dysfunction. Compared with existing medicines, the Tibetan tea extract of the present invention is derived from edible tea, has multiple active ingredients, mild effects, is safe and non-toxic, and has no obvious side effects.

[0023] 3. A pharmaceutical composition for improving, preventing or treating intestinal dysfunction, which is derived from Tibetan tea and can be used, providing a new option for treating, improving or preventing intestinal dysfunction caused by lack of sleep. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 This is a diagram showing the behavioral test results after treatment with Tibetan tea extract;

[0025] Figure 2 This is the DHE staining image of the small intestine and large intestine after treatment with Tibetan tea extract;

[0026] Figure 3 This is a diagram showing the evaluation results of biochemical indicators of the small intestine after treatment with Tibetan tea extract;

[0027] Figure 4 The PAS staining and WB results of the small intestine after treatment with Tibetan tea extract;

[0028] Figure 5 This is the immunohistochemical staining of inflammatory factors in the small intestine after treatment with Tibetan tea extract. DETAILED DESCRIPTION

[0029] The specific embodiments listed in the present invention are only examples of the present invention, and the present invention is not limited to the specific embodiments described below. For those skilled in the art, any equivalent modifications and substitutions to the embodiments described below are also within the scope of the present invention. Therefore, the equal transformations and modifications made without departing from the spirit and scope of the present invention should be included in the scope of the present invention. If the specific conditions are not specified in the embodiments, they are carried out according to the conventional conditions or the conditions recommended by the manufacturer. If the manufacturers are not specified for all reagents or instruments, they are all conventional products that can be purchased commercially. In order to better illustrate the present invention, numerous specific details are given in the specific embodiments below. It should be understood by those skilled in the art that the present invention can also be implemented without certain specific details. In other embodiments, the methods, means, equipment and steps well known to those skilled in the art are not described in detail in order to highlight the purport of the present invention.

[0030] Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art. Unless otherwise specified, the units used in this specification are all international standard units, and the numerical values ​​and numerical ranges appearing in the present invention should be understood to include the inevitable systematic errors in industrial production.

[0031] The Tibetan tea in this application is Ya'an Tibetan tea produced in accordance with the supply and marketing cooperative industry standard GH / T 1120-2015 of the People's Republic of China.

[0032] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.

[0033] Example 1 Preparation of Tibetan Tea Extract

[0034] Prepare according to the following preparation steps:

[0035] Step S1: grind 18 g of ten-year-old dried Tibetan tea leaves with a 40-mesh screen grinder, add 360 ml of pure water, isolate from air, extract in a boiling water bath (90° C.) for 30 minutes, and filter with a 0.45 μm filter membrane to obtain a tea supernatant after cooling;

[0036] Step S2: Place the tea supernatant in a freeze dryer and freeze-dry at -80°C to obtain a freeze-dried powder of Tibetan tea extract. Store in a sealed bottle away from light to reduce unnecessary oxidation and decomposition. Resuspend in ultrapure water and sonicate for 10 minutes before use to obtain a Tibetan tea extract suspension.

[0037] Example 2 Tibetan tea extract effect verification

[0038] Ethical approval from national and local authorities was obtained at West China Hospital before the start of this study.

[0039] 1. Construction and evaluation of sleep deprivation mouse model:

[0040] Sleep deprivation treatment was performed using a new sleep deprivation instrument for mice and rats (Beijing Zhongshidichuang Technology Development Co., Ltd., ZS-SM-Ⅱ). The diameter of the stainless steel rotating rod was 40 cm and fixed in the center of a plastic cage box with a height of 18 cm and a diameter of 40 cm. The rotating rod rotated at a speed of 3 rpm for 12 hours, during which the mice had free access to water and food. The sleep deprivation lasted for 5 days.

[0041] Behavioral evaluation was performed immediately after sleep deprivation. The behavioral evaluation of mice was conducted in the mine field test and the cross-elevation test. All the above test items were carried out using the corresponding dedicated instruments according to the instructions provided by the manufacturer.

[0042] The experimental results are as follows Figure 1 As shown: Figure 1 A, In the elevated plus maze test, we observed the cumulative time that mice stayed in the open arms. Mice with depression and anxiety showed stronger avoidance and fear behaviors towards the open arms. In this experiment, compared with the control group, the SD group mice spent less time in the open arms and more time in the closed arms. Figure 1 As shown in B, C, and D, in the open field experiment, compared with the control group, the SD group mice had a shorter cumulative moving distance in the open field, entered the central area less frequently, and stayed in the central area of ​​the open field for a shorter time. The results showed that the treatment of the sleep deprivation apparatus can significantly affect the behavioral indicators of mice, causing them to be in a state of mental depression.

[0043] 2. Experimental Grouping and Sampling

[0044] In this study, 21 C57BL / 6J mature male commercial mice aged 8-10 weeks and weighing 22-25g were selected. The mice were kept in standard cages (7 per cage), with an ambient temperature of 22-24℃, good ventilation conditions, and a relative humidity of about 50±5%. Commercial mouse feed and drinking water (ultrapure water) were provided, and the supply was unlimited. After 5 days of adaptation to the above conditions, the mice were evenly divided into three groups: control group (Control), sleep deprivation model group (SD) and sleep deprivation + Tibetan tea intervention group (SD+TTE), with 7 mice in each group. The control group was given normal food and water, and 100μL of PBS was given daily by gavage; the model group was given normal food and water, and 100μL of PBS was given daily by gavage and sleep deprivation treatment; the treatment group was given normal food and water, and 100μL of Tibetan tea extract with a concentration of 1.92g / kg was given daily by gavage and sleep deprivation treatment. The mice in each group were treated according to the above method for a total of 5 days.

[0045] After the experiment, mouse plasma was obtained by removing the eyeballs and bleeding, and the mice were killed by cervical dislocation. The small and large intestine tissues were collected for subsequent pathological and biochemical evaluations.

[0046] 3. Mouse intestinal histopathological analysis:

[0047] 3.1 Determination of ROS in mouse intestinal tissue:

[0048] After the mouse intestinal samples were quickly frozen in liquid nitrogen, they were cut into 4 μm thick slices using a freezing microtome. The dihydroethidium (DHE) kit was used to stain and observe the enrichment and distribution of ROS in the small intestine and large intestine tissues of each group of mice. DHE and 4',6-diamidino-2-phenylindole (4',6-diamidino-2-phenylindole, DAPI) fluorescent probes were used for simultaneous staining, and fluorescence was observed and images were collected under a confocal microscope. All samples used the same imaging parameters to collect images, and ImageJ software was used for fluorescence intensity integral analysis. The ratio of DHE fluorescence intensity to DAPI fluorescence intensity in the same picture reflected the content of ROS in the sample. Five sample values ​​were obtained for each group, and three groups were compared. The results are shown in Figure 2 As shown in the figure, compared with the control group, the fluorescence of the large and small intestines in the SD+TTE group was comparable or even lower, but the small intestine tissue of the SD group mice showed more obvious red fluorescence. According to the DHE staining results, it was found that the ROS accumulation in the small intestine caused by sleep deprivation was significantly higher than that in the large intestine. Therefore, the small intestine, which was more severely affected by sleep deprivation, was the main object of analysis in the follow-up.

[0049] 3.2 Quantitative analysis of oxidative stress markers in mouse small intestinal tissue:

[0050] The small intestinal tissues of each group of mice were homogenized, centrifuged and the supernatant solution was obtained. The total protein content in the extract of each tissue sample was determined using the BCA method. ROS, malondialdehyde (MDA), and superoxide dismutase (SOD) test kits were used to detect the corresponding indicators in the extract of each sample according to the instructions provided by the manufacturer. MDA is a product of lipid peroxidation and can be used to assess the degree of oxidative stress. The higher the degree of oxidative stress, the greater its content. SOD is a type of antioxidant metalloenzyme present in organisms. It plays a vital role in the balance of oxidation and antioxidant in the body. When the degree of oxidative stress increases, its activity consumption will be enhanced. The results are as follows: Figure 3 As shown in the results, after sleep deprivation, the ROS level and MDA content in the small intestine of mice were significantly increased compared with the normal group (0.025μmol / g VS 0.044μmol / g, p<0.05), and the SOD activity level was significantly reduced (1552U / g VS1188U / g, p<0.05). After TTE intervention, these three indicators were all adjusted back to near normal levels. The results show that sleep deprivation does cause significant oxidative stress in the intestine of mice, and oral intervention with TTE can effectively alleviate this intestinal oxidative stress.

[0051] 3.3 Evaluation of intestinal barrier function of mouse small intestinal tissue:

[0052] In order to observe the effect of Tibetan tea extract on the pathology of small intestinal mucosa, periodic acid-schiff (PAS) histological staining was further performed on the small intestine. The small intestinal tissues from the three groups of mice were fixed in 10% neutral buffered formalin for 48 hours. Subsequently, the specimens were dehydrated and placed in paraffin, and then cut into 4μm thickness. Subsequently, the sections were stained with PAS and observed under a microscope, and the number of goblet cells per unit area of ​​each group of tissue sections was counted; then, Western blot (WB) experiments were used to analyze the expression of small intestinal mucosal barrier function proteins MUC2 and Occludin. Figure 4 As shown in the results, compared with the control group, sleep deprivation significantly reduced the expression of intestinal barrier function-related proteins MUC2 (1±0.21VS 0.31±0.25) and Occludin (1±0.09VS 0.24±0.07). After TTE intervention, the expression of these two proteins effectively recovered to the same level as the control group. The above pathological analysis and protein expression analysis experimental results show that TTE intervention can effectively improve the intestinal barrier dysfunction of mice caused by sleep deprivation.

[0053] 3.4 Evaluation of inflammatory factors in mouse tissues

[0054] Immunohistochemistry was used to stain the small intestine tissue to reveal the different distribution of three inflammatory factors, tumor necrosis factor α (TNF-α), interleukin 6 (IL-6), and interleukin 1β (IL-1β), in the small intestine of the three groups of mice. The staining was performed using the corresponding kits according to the instructions provided by the manufacturer. The results are shown in Figure 2. Figure 5 As shown in the figure, compared with the control group, the inflammatory factors IL-1β, IL-6 and TNF-α were significantly increased in mice after sleep deprivation. After TTE intervention, these four inflammatory factors were significantly adjusted back or even close to normal levels. The above experimental results show that the potential damage of sleep deprivation to the intestine can cause the increase of a series of inflammatory factors in the intestine of mice, and TTE intervention can effectively alleviate this damage.

[0055] 2. Experimental results

[0056] Generally speaking, the technology of constructing an intestinal inflammation and barrier dysfunction model using mice is a mature and widely used in vivo model. This patent illustrates the successful establishment of an intestinal inflammation and barrier dysfunction model in mice by using sleep deprivation through behavioral and pathological methods, which is conducive to further exploring the therapeutic effect of Tibetan tea extract on intestinal inflammation and barrier dysfunction caused by sleep deprivation.

[0057] Further research results of this application show that Tibetan tea extract can inhibit oxidative damage by clearing ROS in the intestine, while inhibiting the production and release of inflammatory factors and reducing intestinal permeability, thereby improving intestinal barrier dysfunction caused by oxidative stress and protecting intestinal health.

[0058] In summary, the present invention provides a Tibetan tea extract, which is proven to have an effective therapeutic effect on intestinal inflammation and barrier dysfunction, and provides a new option for the clinical treatment of intestinal inflammation and barrier dysfunction.

[0059] The above-mentioned embodiments only express the specific implementation methods of the present application, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the protection scope of the present application. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the technical solution concept of the present application, and these all belong to the protection scope of the present application.

Claims

1. Use of Tibetan tea in preparing a medicine for improving, preventing or treating intestinal dysfunction.

2. The use of Tibetan tea according to claim 1 in preparing a medicine for improving, preventing or treating intestinal dysfunction, characterized in that: The intestinal dysfunction is induced by sleep deprivation.

3. A pharmaceutical composition for improving, preventing or treating intestinal dysfunction, characterized in that: The pharmaceutical composition comprises a Tibetan tea extract.

4. A pharmaceutical composition for improving, preventing or treating intestinal dysfunction according to claim 3, characterized in that: The Tibetan tea extract is prepared according to the following method: Step S1: grind the Tibetan tea with a 40-mesh screen grinder to obtain tea powder; Step S2: Mix water and tea powder in a mass ratio of 20:1, isolate from air, extract in a boiling water bath at 90-100° C. for 30 minutes, and filter through a 0.45 μm filter membrane after cooling to obtain a tea supernatant; Step S3: Dry the tea supernatant to remove water to obtain the Tibetan tea extract.

5. A pharmaceutical composition for improving, preventing or treating intestinal dysfunction according to claim 4, characterized in that: In step S3, the drying method is freeze-drying at -80°C to obtain the Tibetan tea extract.

6. A pharmaceutical composition for improving, preventing or treating intestinal dysfunction according to claim 3, characterized in that: The intestinal dysfunction is induced by sleep deprivation.

7. A pharmaceutical composition for improving, preventing or treating intestinal dysfunction according to claim 3, characterized in that: The intestinal dysfunction is characterized by accumulation of intestinal reactive oxygen species, increased oxidative stress marker MDA, decreased SOD activity, damaged intestinal goblet cells, and increased inflammatory factors.

8. The pharmaceutical composition for improving, preventing or treating intestinal dysfunction according to claim 3, characterized in that: The Tibetan tea is ten-year aged Tibetan tea.

Citation Information

Patent Citations

  • Composition regulating lipid metabolism disorder, preparation method and use thereof

    CN110604773A